Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000041714 | SCV000065410 | pathogenic | Rare genetic deafness | 2012-08-28 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000670554 | SCV000795417 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2017-11-14 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001057968 | SCV001222499 | pathogenic | not provided | 2023-09-03 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 48392). Disruption of this splice site has been observed in individuals with clinical features of Usher syndrome (PMID: 30459346; Invitae). This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change affects an acceptor splice site in intron 62 of the USH2A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001074339 | SCV001239914 | likely pathogenic | Retinal dystrophy | 2019-07-12 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001057968 | SCV001777205 | pathogenic | not provided | 2021-05-05 | criteria provided, single submitter | clinical testing | Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); Reported in ClinVar as pathogenic or likely pathogenic but additional evidence is not available (SCV000065410.5, SCV000795417.1; Landrum et al., 2016); Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV003445119 | SCV004173914 | likely pathogenic | Retinitis pigmentosa 39 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001826587 | SCV004173915 | likely pathogenic | Usher syndrome type 2A | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003445119 | SCV004208246 | likely pathogenic | Retinitis pigmentosa 39 | 2024-03-21 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001826587 | SCV002088313 | pathogenic | Usher syndrome type 2A | 2021-06-08 | no assertion criteria provided | clinical testing |